Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEK4HZ)

Drug Name

C5aR pepducins Drug Info

Synonyms

C5aR pepducins ((lipopeptide, inflammatory diseases); Component 5a receptor modulators (lipopeptide, inflammatory diseases), Anchor Therapeutics; C5aR pepducins ((lipopeptide, inflammatory diseases), Anchor Therapeutics

Indication

Disease Entry	ICD 11	Status	REF
Inflammation	1A00-CA43.1	Investigative	[1]

Cross-matching ID

TTD Drug ID: DMEK4HZ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C5a anaphylatoxin chemotactic receptor (C5AR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avacopan	DM5LQHB	Anca-associated vasculitis	4A44.A	Approved	[2]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[3]
NN8209	DM2TDE7	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[4]
NN8210	DM8Z5VH	Rheumatoid arthritis	FA20	Discontinued in Phase 1	[4]
PMX205	DMMXR3L	Central nervous system disease	8A04-8D87	Preclinical	[5]
RPR121154	DM9DXHM	Discovery agent	N.A.	Investigative	[1]
W54011	DMQI7BA	Discovery agent	N.A.	Investigative	[6]
NDT9520492	DMFKX7Z	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C5a anaphylatoxin chemotactic receptor (C5AR1)	TTHXFA1	C5AR1_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 32).
2	Clinical pipeline report, company report or official report of ChemoCentryx.
3	Company report (Arana Therapeutics)
4	Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013 Apr 15;190(8):3839-47.
5	Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice. Sci Rep. 2018 May 25;8(1):8101.
6	Identification of a potent and orally active non-peptide C5a receptor antagonist. J Biol Chem. 2002 Dec 20;277(51):49403-7.
7	Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule ... J Biol Chem. 2005 Dec 9;280(49):40617-23.